| Document |
Document Title |
|
WO/2013/072830 |
The present invention discloses single step, highly enantioselective catalytic oxidative cyclization process for the synthesis of 3-substituted chiral phthalides. In particular, the invention discloses asymmetric synthesis of chiral phth...
|
|
WO/2013/069646 |
The purpose of the invention is to provide a polyimide offering excellent solubility in organic solvents, an acid dianhydride compound that is a monomer thereof, and a method for producing the same. An acid dianhydride represented by for...
|
|
WO/2013/067578 |
Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated card...
|
|
WO/2013/066776 |
Processes for producing 5-(hydroxymethyl)furfural are provided. 5-(hydroxymethyl)furfural is a potential platform intermediate in the conversion of biomass to renewable chemicals. The processes use hexoses in an aqueous solution comprisi...
|
|
WO/2013/066541 |
Processes for producing furfural from biomass are provided. The processes use a metal halide in aqueous solutions of water-miscible and can provide a furfural yield of greater than 70%.
|
|
WO/2013/064610 |
The invention relates to a process for the production of gamma-valerolactone (GVL) by gas phase hydrogenation of furfural or furfuryl alcohol in the presence of a solid catalyst. The conversion of furfural or furfuryl alcohol to GVL is c...
|
|
WO/2013/064751 |
The present invention relates to a method and an arrangement for separation and recovery of at least one carboxylic acid and furfural from a dilute aqueous mixture thereof. In the method of the present invention a dilute aqueous mixture ...
|
|
WO/2013/065835 |
A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. This novel compound has an ability of activating a glycogen synthase, but rarely activates a receptor, i.e., a PPAR, and is highly safe. (In the...
|
|
WO/2013/061724 |
Provided are a novel radical inhibitor, a composition containing the same, and a radical generation inhibition method using the same. This radical inhibitor comprises a salen complex compound of a divalent metal.
|
|
WO/2013/061962 |
The present invention provides a compound represented by formula (I) or a salt thereof. (In the formula, the symbols are as defined in the description.)
|
|
WO/2013/060860 |
The present invention relates to compounds having the general formula (I) as described herein; methods of preparing said compounds; and their use in treating Type 1 and/or Type 2 Diabetes Mellitus. The compounds were assayed for binding ...
|
|
WO/2013/061004 |
The present invention relates to novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to the following general formula (I): , to the pharmaceutical compositions containing these compounds and also to the use of...
|
|
WO/2013/061224 |
The present invention provides a novel process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren, or a salt thereof, preferably Aliskiren hemifumarate.
|
|
WO/2013/059582 |
The disclosure relates to small molecules and methods, compositions, and kits comprising these small molecules. In still another embodiment, the disclosure relates to small molecules that inhibit HDAC activity. In yet another embodiment,...
|
|
WO/2013/059215 |
Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds.
|
|
WO/2013/058631 |
The present invention relates to a diterpene furanoids compound which inhibits an activity of protein tyrosine phosphatase 1B (PTP1B) and to the use thereof. More particularly, the present invention relates to diterpene furanoids which a...
|
|
WO/2013/053046 |
The present application, relates to iron bisphenolate complexes and methods of use and synthesis thereof. The iron complexes are prepared from tridentate or tetradentate ligands of Formula I: wherein R1 and R2 are as defined herein. Also...
|
|
WO/2013/053287 |
(-)-(S)-3-(3'-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-impro...
|
|
WO/2013/053816 |
The present invention relates to a process for producing 5-hydroxymethylfurfural (HMF) from fructose in a single-phase aqueous solution comprising an organic solvent.
|
|
WO/2013/055577 |
The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.
|
|
WO/2013/050301 |
The present invention relates to processes for the enantio-selective preparation of spyrrolidine derivatives useful in the manufacture of pesticidally active compounds, as well as to intermedates in the processes. The processes include t...
|
|
WO/2013/044371 |
A compound according to Formula IA and IB, reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer A and a ring-closed isomer B is provided. For substitutent groups, Z is N, O or S; each R1 is i...
|
|
WO/2013/047904 |
The present invention provides a novel compound having a control efficacy on harmful arthropods. A compound represented by Formula (I): wherein Y represents a 3-7-membered saturated heterocyclic group containing one or more atoms or grou...
|
|
WO/2013/049711 |
Provided are methods of producing 2,5-furandicarboxylic acid (FDCA) from renewable sources such as seaweed, alginate, oligoalginate, pectin, oligopectin, polygalacturonate, galacturonate, and/or oligogalacturonate. The sugars in the rene...
|
|
WO/2013/047055 |
Provided is a heat shock protein expression inducer based on a heat shock protein (HSP) expression-inducing action. The present invention is a heat shock protein (HSP) expression inducer comprising eupalinolide A and/or B, the heat shock...
|
|
WO/2013/047044 |
The present invention is a composition for forming a film for liquid-immersion exposure, said composition containing the following: a polymer component (A) containing a polymer (a1) that has a constitutional unit (I) represented by diagr...
|
|
WO/2013/047984 |
The present invention relates to a method for producing a furan-based compound using an ion exchange resin in the presence of an organic solvent. In the method for producing a furan-based compound according to the present invention, a fu...
|
|
WO/2013/042769 |
This aromatic amine derivative is represented by general formula (1). In general formula (1), R2, R3, R4, R5, R7, R8, R9, and R10 each independently are a hydrogen atom or a substituent group. In general formula (1): R1 and R6 are repres...
|
|
WO/2013/041807 |
The present invention relates to compounds having the following formula (I-I): in which A represents a cycle chosen from the group comprising the aryl, heteroaryl, C5-8 cycloalkenyl, and heterocycloalkenyl groups, said cycle (A) being op...
|
|
WO/2013/041895 |
The invention relates to novel compounds of general formula (I), and their preparation, pharmaceutical preparations containing compounds of general formula (I), and the use of these compounds in therapeutic procedures. The invention also...
|
|
WO/2013/043131 |
Disclosed herein is a process for preparing 5-hydroxymethylfurfural comprising the step of contacting a carbohydrate and a Brønsted acid in an alcoholic solvent comprising an alcohol selected from the group consisting of secondary alcoh...
|
|
WO/2013/042124 |
Compound of formula X wherein P1 is a fused-ring system comprising one 6-membered and two 5- membered rings; v indicates an S or R configuration; or individual isomers or pharmaceutically acceptable salts thereof, or mixtures thereof, in...
|
|
WO/2013/042775 |
An aromatic amine derivative represented by general formula (1-1). In general formula (1-1), R2-R5 and R7-R10 are each independently a hydrogen atom or a substituent group. In general formula (1-1), R1 and R6 are represented by general f...
|
|
WO/2013/042138 |
A process for the preparation of 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl) tetrahydro-5-(lH-l,2,4-triazol-l-ylmefhyl) -3-furanyl]mefhoxy] phenyl] -1 -piperazinyl] phenyl]-2-[(lS,2S)-l-efhyl-2-hydroxypropyl]-2,4-dihydro-3H-l
,2,4-triazo...
|
|
WO/2013/040068 |
The presently disclosed subject matter provides methods of preparing synthetic prostacyclin analogues, including Beraprost, either as racemic mixtures or as single stereoisomers. Also provided are novel synthetic intermediates for use in...
|
|
WO/2013/039184 |
An aromatic amine derivative represented by general formula (1). In general formula (1), R1 to R10 each independently are a hydrogen atom or a substituent group. In general formula (1), any one of R1 to R10 is represented by general form...
|
|
WO/2013/040540 |
A composition comprising between 95 and 100% biobased succinic acid, MAS or DAS wherein at least 75 % of the carbons are biobased.
|
|
WO/2013/040068 |
The presently disclosed subject matter provides methods of preparing synthetic prostacyclin analogues, including Beraprost, either as racemic mixtures or as single stereoisomers. Also provided are novel synthetic intermediates for use in...
|
|
WO/2013/039221 |
An aromatic amine derivative represented by general formula (1). In general formula (1), R1 to R10 each independently are a hydrogen atom or substituent group. In general formula (1), R1 is represented by general formula (2), and any one...
|
|
WO/2013/038430 |
Disclosed herein is 10-α/β-D-Arabinofuranosylundecenes of general Formula (II) or pharmaceutically acceptable salts thereof as anti-mycobacterial agents in vitro; (II) wherein R, R1 and R" are as defined herein in the specification. Th...
|
|
WO/2013/038931 |
This method of cheaply and easily producing a 2-oxo-2H-cyclohepta[b]furan analogue useful as a pharmaceutical intermediate with high purity and high yields. In this method, a 2-oxo-2H-cyclohepta[b]furan analogue represented by general fo...
|
|
WO/2013/038650 |
A compound represented by formula (1). (In the formula, A1 represents O, S, Si(Ar1)(Ar2), P(=O)(Ar3)(Ar4), a substituted or unsubstituted arylene group having 6 to 30 ring-forming carbon atoms, or a substituted or unsubstituted heteroary...
|
|
WO/2013/033971 |
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, ...
|
|
WO/2013/034048 |
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, ...
|
|
WO/2013/033899 |
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, ...
|
|
WO/2013/033058 |
A process is provided for carrying out an oxidation on a sprayable feed including a furanic substrate to be oxidized and a catalytically effective combination of cobalt, manganese, and bromide components for catalyzing the oxidation of t...
|
|
WO/2013/029479 |
Disclosed in the present invention is a mycophenolic acid derivative shown by the following general formula (V) and the pharmaceutically acceptable salts thereof, wherein L1 is -O-R2, -QCOOR2 or -QCONR2R3, Q is C1~C10. Alkylidene or C1~C...
|
|
WO/2013/029555 |
Provided are lavendustin A derivatives, a preparation method and use thereof. The compounds are shown by the structure of formula (I), wherein R is alkyl, ether group, carbonyl, p-tolyl, five-membered heterocyclic group, five-membered su...
|
|
WO/2013/030131 |
The invention relates to a method for producing furfural by reacting pentose in water and in the presence of carboxylic acid and a heterogeneous acid catalyst, said method being carried out in an aqueous solution of carboxylic acid as th...
|
|
WO/2013/033081 |
A process is provided for carrying out an oxidation on a feed including levulinic acid and/or a levulinic acid oxidation precursor to succinic acid, one or more furanic oxidation precursors of 2,5-furandicarboxylic acid and a catalytical...
|
